These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 28670113)

  • 1. Long-term natalizumab treatment is associated with sustained improvements in quality of life in patients with multiple sclerosis.
    Foley JF; Nair KV; Vollmer T; Stephenson JJ; Niecko T; Agarwal SS; Watson C
    Patient Prefer Adherence; 2017; 11():1035-1048. PubMed ID: 28670113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life in multiple sclerosis: effects of natalizumab.
    Rudick RA; Miller D; Hass S; Hutchinson M; Calabresi PA; Confavreux C; Galetta SL; Giovannoni G; Havrdova E; Kappos L; Lublin FD; Miller DH; O'Connor PW; Phillips JT; Polman CH; Radue EW; Stuart WH; Wajgt A; Weinstock-Guttman B; Wynn DR; Lynn F; Panzara MA;
    Ann Neurol; 2007 Oct; 62(4):335-46. PubMed ID: 17696126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab: A 3-year follow-up multicentric study.
    Planche V; Moisset X; Morello R; Dumont E; Gibelin M; Charré-Morin J; Saubusse A; Mondou A; Reuter F; Defer G; Pelletier J; Brochet B; Clavelou P
    J Neurol Sci; 2017 Nov; 382():148-154. PubMed ID: 29111011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.
    Perumal J; Fox RJ; Balabanov R; Balcer LJ; Galetta S; Makh S; Santra S; Hotermans C; Lee L
    BMC Neurol; 2019 Jun; 19(1):116. PubMed ID: 31176355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab is associated with early improvement of working ability in relapsing-remitting multiple sclerosis patients: WANT observational study results.
    Capra R; Morra VB; Mirabella M; Gasperini C; Scandellari C; Totaro R; De Rossi N; Masera S; Zipoli V; Patti F;
    Neurol Sci; 2021 Jul; 42(7):2837-2845. PubMed ID: 33205373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study.
    Meca-Lallana JE; Prieto González JM; Caminero Rodríguez AB; Olascoaga Urtaza J; Alonso AM; Durán Ferreras E; Espinosa R; Dotor J; Romera M; Ares Luque A; Pérez Ruiz D; Calles C; Hernández MA; Hervás García M; Mendoza Rodríguez A; Berdei Montero Y; Téllez N; Herrera Varó N; Sotoca J; Presas-Rodríguez S; Querol Gutierrez LA; Hervás Pujol M; Batlle Nadal J; Martín Ozaeta G; Gubieras Lillo L; Martínez Yélamos S; Ramió-Torrentà L; Mallada Frechin J; Belenguer Benavides A; Gascón-Giménez F; Casanova B; Landete Pascual L; Berenguer L; Navarro L; Gómez Gutierrez M; Durán C; Rodríguez Regal A; Álvarez E; García-Estévez DA; López Real AM; Llaneza González MA; Marzo Sola ME; Sánchez-Menoyo JL; Oterino A; Villaverde González R; Castillo-Triviño T; Álvarez de Arcaya A; Llarena C
    Neurol Ther; 2023 Dec; 12(6):2177-2193. PubMed ID: 37861931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of delayed-release dimethyl fumarate (DMF) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies.
    Kita M; Fox RJ; Gold R; Giovannoni G; Phillips JT; Sarda SP; Kong J; Viglietta V; Sheikh SI; Okwuokenye M; Kappos L
    Clin Ther; 2014 Dec; 36(12):1958-1971. PubMed ID: 25315404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study.
    Perumal J; Balabanov R; Su R; Chang R; Balcer LJ; Galetta SL; Avila RL; Rutledge D; Fox RJ
    CNS Drugs; 2022 Sep; 36(9):977-993. PubMed ID: 36064841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erratum.
    Mult Scler; 2016 Oct; 22(12):NP9-NP11. PubMed ID: 26041800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of natalizumab on patient-reported outcomes in multiple sclerosis: a longitudinal study.
    Stephenson JJ; Kern DM; Agarwal SS; Zeidman R; Rajagopalan K; Kamat SA; Foley J
    Health Qual Life Outcomes; 2012 Dec; 10():155. PubMed ID: 23270428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosis.
    Cohen JA; Krishnan AV; Goodman AD; Potts J; Wang P; Havrdova E; Polman C; Rudick RA
    JAMA Neurol; 2014 Nov; 71(11):1386-93. PubMed ID: 25178496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patient-centered outcomes: translating clinical efficacy into benefits on health-related quality of life.
    Miller D; Rudick RA; Hutchinson M
    Neurology; 2010 Apr; 74 Suppl 3():S24-35. PubMed ID: 20421570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health perceptions and clinical characteristics of relapsing-remitting multiple sclerosis patients: baseline data from an international clinical trial.
    Robinson D; Zhao N; Gathany T; Kim LL; Cella D; Revicki D
    Curr Med Res Opin; 2009 May; 25(5):1121-30. PubMed ID: 19317608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study.
    Willian MK; D'Haens G; Yarlas A; Joshi AV
    J Patient Rep Outcomes; 2018 Dec; 2():22. PubMed ID: 30294708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction to: Improvements in Cognitive Processing Speed, Disability, and Patient‑Reported Outcomes in Patients with Early Relapsing‑Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4‑year, Real‑World, Open‑Label Study.
    Perumal J; Balabanov R; Su R; Chang R; Balcer LJ; Galetta SL; Avila RL; Rutledge D; Fox RJ
    CNS Drugs; 2023 Mar; 37(3):275-289. PubMed ID: 36780107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.
    Trojano M; Butzkueven H; Kappos L; Wiendl H; Spelman T; Pellegrini F; Chen Y; Dong Q; Koendgen H; Belachew S;
    Mult Scler Relat Disord; 2018 Aug; 24():11-19. PubMed ID: 29860197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of natalizumab on patient-reported outcomes in a clinical practice setting: a cross-sectional survey.
    Kamat SA; Rajagopalan K; Stephenson JJ; Agarwal S
    Patient; 2009 Jun; 2(2):105-12. PubMed ID: 22273086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of natalizumab in real-world clinical practice: Review of observational studies.
    van Pesch V; Sindic CJ; Fernández O
    Clin Neurol Neurosurg; 2016 Oct; 149():55-63. PubMed ID: 27475049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of disability with quality of life in patients with multiple sclerosis treated with natalizumab: primary results and post hoc analysis of the TYSabri ImPROvement study (PROTYS).
    Achtnichts L; Zecca C; Findling O; Kamm CP; Mueller S; Kuhle J; Lutterotti A; Gobbi C; Viviani C; Villiger-Borter E; Nedeltchev K
    BMJ Neurol Open; 2023; 5(1):e000304. PubMed ID: 36727105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of peginterferon beta-1a and disease factors on quality of life in multiple sclerosis.
    Newsome SD; Guo S; Altincatal A; Proskorovsky I; Kinter E; Phillips G; You X; Sabatella G
    Mult Scler Relat Disord; 2015 Jul; 4(4):350-7. PubMed ID: 26195056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.